Prognostic Significance of Basal Markers in Triple-negative Breast Cancers

Kim, Jun Mo; Hwang, Tae Yoon; Kang, Su Hwan; Lee, Soo Jung; Bae, Young Kyung

doi:10.4048/jbc.2009.12.1.4

Cited by 12 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other biomarkers including PgR, Ki67, p53 and EGFR also showed prognostic significance on univariate analysis, but were absorbed into ER in multivariate analysis. EGFR has recently received much attention as a therapeutic target in triple-negative disease, where it may have a role to play in older women (Tan et al , 2008; Kim et al , 2009; Lee et al , 2010). Further studies may give some insights into this.…”

Section: Discussionmentioning

confidence: 99%

Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

et al. 2013

View full text Add to dashboard Cite

Background:As age advances breast cancer appears to change its biological characteristics, however, very limited data are available to define the precise differences between older and younger patients.Methods:Over 36 years (1973–2009), 1758 older (⩾70 years) women with early operable primary breast cancer were managed in a dedicated clinic. In all, 813 underwent primary surgery and 575 good quality tumour samples were available for biological analysis. The pattern of biomarkers was analysed using indirect immunohistochemistry on tissue microarrays. Comparison was made with a previously characterised series of younger (<70 years) patients.Results:There was high expression of oestrogen receptor (ER), PgR, Bcl2, Muc1, BRCA1 and 2, E-cadherin, luminal cytokeratins, HER3, HER4, MDM2 and 4 and low expression of human epidermal growth factor receptor (HER)-2, Ki67, p53, EGFR and CK17. Oestrogen receptor and axillary stage appeared as independent prognostic factors. Unsupervised partitional clustering showed six biological clusters in older patients, five of which were common in the younger patients, whereas the low ER luminal cluster was distinct in the older series. The luminal phenotype showed better breast cancer-specific survival, whereas basal and HER2-overexpressing tumours were associated with poor outcome.Conclusion:Early operable primary breast cancer in older women appears as a distinct biological entity, with existence of a novel cluster. Overall older women showed less aggressive tumour biology and ER appeared as an independent prognostic factor alongside the time-dependent axillary stage. These biological characteristics may explain the differences in clinical outcome and should be considered in making therapeutic decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

et al. 2013

View full text Add to dashboard Cite

show abstract

“…With approximately 70–90% of triple-negatives revealed to be basal-like breast carcinomas [ 36 , 37 ], TNP has been frequently used as a surrogate for the basal-like subtype. However, despite considerable overlap in behavioral/biological characteristics, several studies have shown that triple-negative and basal-like breast tumors are not synonymous, differing in prognosis and possibly in chemotherapeutic sensitivity [ 12 , 38 , 39 , 40 , 41 ]. Furthermore, an all-negative definition has a high propensity to mis-assign tumor classifications when biomarkers are negative for technical reasons.…”

Section: Biomarker Panels For Basal-like Breast Cancermentioning

confidence: 99%

Biomarkers for Basal-like Breast Cancer

Choo

Nielsen

2010

Cancers

View full text Add to dashboard Cite

Initially recognized through microarray-based gene expression profiling, basal-like breast cancer, for which we lack effective targeted therapies, is an aggressive form of carcinoma with a predilection for younger women. With some success, immunohistochemical studies have attempted to reproduce the expression profile classification of breast cancer through identification of subtype-specific biomarkers. This review aims to present an in depth summary and analysis of the current status of basal-like breast cancer biomarker research. While a number of biomarkers show promise for future clinical application, the next logical step is a comprehensive investigation of all biomarkers against a gene expression profile gold standard for breast cancer subtype assignment.

show abstract

“…EGFR은 세포막에 존재하 며, 리간드와 결합하는 세포 외 영역, 친 지질성 세포막 영역, tyrosin kinase 활성이 있는 세포 내 영역으로 구성되어 있으며, 1 EGFR (ErbB1), Her2/neu (ErbB2), Her3 (ErbB3), Her4 (ErbB4) 등 4개의 비슷한 EGFR family 단백질에 속한다. 2,3 또한 EGFR은 폐암, 유방암, 대장암, 두경부 악성 종양, 난소 암, 방광암, 자궁경부암 등 다양한 악성 종양에서 발현이 증가되 는데, [4][5][6][7] 대장암에서 EGFR의 발현율은 25-77%로 연구자들에 따라 다양하며, 임상병리학적 의의 또한 상반된 결과가 많다. 8 이와 같은 다양한 결과는 EGFR 항체의 종류 및 실험 조건의 차이 그리고 대상 증례의 다양성으로 인해 발생할 뿐만 아니라, 동일한 실험 조건 내에서도 EGFR 염색의 양성 판독 기준에 의 해 많은 차이가 있을 수 있다.…”

Section: 대장암의 침습적 경계면에서 Egfr 발현의 임상병리학적 의의unclassified

Clinicopathologic Significances of EGFR Expression at Invasive Front of Colorectal Cancer

et al. 2010

View full text Add to dashboard Cite

Background : Epidermal growth factor receptor (EGFR) is frequently expressed in the invasive front of colorectal cancer (CRC), but its clinicopathologic significance remains unclear. We investigated the clinical value of the EGFR expression at the invasive front of CRC. Methods :We performed an immunohistochemical analysis in order to examine the expression and distribution of EGFR in 214 cases of CRC. The EGFR status was considered positive when ≥ 1% of the tumor cells had membranous staining. Results : Overall, an EGFR expression was observed in 144 (67%) cases and it had no significant relationship with the clinicopathologic parameters. However, an EGFR expression at the invasive front was correlated with lymphatic invasion, lymph node metastasis and a high level of serum carcinoembryonic antigen (p = 0.028, p = 0.043, and p = 0.045, respectively). For the budding-positive CRCs liver metastases were found in the cases with an EGFR expression at the budding, but no liver metastasis occurred in the EGFR negative cases at the budding (p = 0.030). Conclusions : An EGFR expression at the invasive front has clinicopathologic significances in patients with CRC. An EGFR expression at tumor cell budding is a pathologic marker that suggests the high potential for liver metastasis in CRC.

show abstract

Prognostic Significance of Basal Markers in Triple-negative Breast Cancers

Cited by 12 publications

References 39 publications

Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

Biomarkers for Basal-like Breast Cancer

Clinicopathologic Significances of EGFR Expression at Invasive Front of Colorectal Cancer

Contact Info

Product

Resources

About